TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02120222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
Study: NCT02570022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Local infiltration of liposomal bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inter-scalene nerve block
Description: Pre-operative inter-scalene nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivicaine was used for the inter-scalene nerve block.
Study: NCT01070069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEVAR (ProGlide closure)
Description: Percutaneous EVAR facilitated by the ProGlide closure device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEVAR (IntuiTrak)
Description: Standard vascular exposure for access prior to EVAR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEVAR (Prostar XL closure)
Description: Percutaneous EVAR facilitated by the Prostar XL closure device
Study: NCT04110223

Intervention type: GENETIC
Intervention: next generation sequence
Description: targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.

Intervention type: GENETIC
Intervention: next generation sequence
Description: targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.

Intervention type: GENETIC
Intervention: next generation sequence
Description: targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.

Intervention type: GENETIC
Intervention: next generation sequence
Description: targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.

Intervention type: GENETIC
Intervention: next generation sequence
Description: targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.

Intervention type: GENETIC
Intervention: next generation sequence
Description: targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
Study: NCT00645918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
Study: NCT01079286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir and temsirolimus
Description: Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
Study: NCT01360762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
Study: NCT03534726

Intervention type: DEVICE
Intervention: 7 T CMR
Description: 7 tesla MRI device
Study: NCT01610453

Intervention type: PROCEDURE
Intervention: ultrasound examination
Description: transabdominal and transperineal ultrasound examinations
Study: NCT03234894

Intervention type: DEVICE
Group type: OTHER
Intervention: SiteSeal Endovascular
Description: to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
Study: NCT04385056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCTC-0010
Description: MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCTC-0010
Description: MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCTC-0010
Description: MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
Study: NCT00462358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: Part 1: standard of care; Part 2: standard of care.
Study: NCT01306786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple therapy
Description: First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple therapy
Description: First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
Study: NCT02729506

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Radioembolization
Description: Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization using drug-eluting beads
Description: TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device.
Study: NCT04092231

Intervention type: BEHAVIORAL
Intervention: Early speech perception test
Description: The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
Study: NCT01084707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: Oral Nicotine either self-administered or provided by study personnel within 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: Oral Nicotine either self-administered or provided by study personnel within 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Nicotine
Description: Oral Nicotine either self-administered or provided by study personnel within 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Description: Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
Study: NCT01137708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)
Description: Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
Study: NCT04992364

Intervention type: OTHER
Intervention: Burnout and Clinical performances questionnaires
Description: Subjects were given questionnaires to assess burnout score and clinical performances

Intervention type: OTHER
Intervention: Burnout and Clinical performances questionnaires
Description: Subjects were given questionnaires to assess burnout score and clinical performances
Study: NCT02152735

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning the uterine cavity
Description: These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
Study: NCT02377635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anhydrous selenite
Description: 40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: 40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
Study: NCT01739296

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral insole with subtalar strapping (sham)
Description: Neutral insole with subtalar strapping (sham)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole with subtalar strapping
Description: Lateral wedge insole with subtalar strapping
Study: NCT00400361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
Study: NCT02954926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
Study: NCT03374241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM15211 or Placebo
Description: Long-acting tri-agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM15211 or Placebo
Description: Long-acting tri-agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM15211 or Placebo
Description: Long-acting tri-agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM15211 or Placebo
Description: Long-acting tri-agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM15211 or Placebo
Description: Long-acting tri-agonist
Study: NCT01558336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: praziquantel
Description: praziquantel 40 mg/kg oral tablets
Study: NCT01660334

Intervention type: DRUG
Intervention: Voriconazole
Description: Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
Study: NCT03336320

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICT Multidomain Intervention Training
Description: Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICT Multidomain Intervention Training
Description: Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
Study: NCT04366856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1: Prone positioning
Description: the interventional group will be suggested to spend at least 6 hours a day in prone position

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 2: No instruction regarding positioning
Description: group with no instruction regarding positioning (control group)
Study: NCT00654537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Study: NCT02998450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: 1 of 6 possible single doses administered orally following overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: 1 of 6 possible single doses administered orally following overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: 1 of 6 possible single doses administered orally following overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: 1 of 6 possible single doses administered orally following overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: 1 of 6 possible single doses administered orally following overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: 1 of 6 possible single doses administered orally following overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
Study: NCT03066115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: See arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: See arm description.
Study: NCT02998450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
Study: NCT03676517

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative short-course radiotherapy
Description: 1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
Study: NCT02470793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Descemet Stripping Automated Endothelial Keratoplasty
Description: Descemet Stripping Automated Endothelial Keratoplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Endothelial Keratoplasty
Description: Descemet Membrane Endothelial Keratoplasty
Study: NCT03150823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upward Direct Current (Ascending Effect)
Description: Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downward Direct Current (Descending Effect)
Description: Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
Study: NCT01839175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexavalent vaccine
Description: 0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hexavalent vaccine
Description: 0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
Study: NCT03150823

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Direct Current
Description: Installation of electrotherapy equipment off (Sham tratment).
Study: NCT05068375

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombophilia screening
Description: Genetic thrombophilia and acquired thrombophilia screening
Study: NCT01370135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg intraocular Ranibizumab (Lucentis)
Description: short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
Study: NCT02002000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (cholecalciferol)
Description: Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, similar in appearance and taste to cholecalciferol
Description: Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
Study: NCT02979236

Intervention type: DEVICE
Intervention: STENTYS Xposition S
Study: NCT02593448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS during VOT
Description: Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIRS during VOT
Description: Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB.
Study: NCT00654537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study: NCT01459094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)
Description: Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.